Small molecule screening as an approach to encounter inefficient myelin repair

While current multiple sclerosis therapies are focused on immunomodulation, thereby slowing down disease progression, scientific interest has nowadays been shifted toward regenerative therapies aiming at reversing already existing deficits. The application of chemical compounds was proven to be valuable for the understanding of oligodendrogenesis and for exposing mechanisms that can boost remyelination. However, sufficient myelin repair has not been achieved yet, thus underscoring the need for more studies toward this unmet clinical goal. In this regard, many research groups have significantly contributed to the field via developing compound screening approaches or using single substances. We, here, present an overview of recent studies addressing the identification of myelin repair drugs and provide insights into technical aspects and identified substances.

Automated summary

Current focus in multiple sclerosis treatment has shifted towards regenerative therapies to reverse existing deficits, with a growing interest in understanding oligodendrogenesis and mechanisms promoting remyelination. While progress has been made in this area, achieving sufficient myelin repair remains a challenge, underscoring the need for further research towards this clinical goal. Many research groups have contributed significantly to this field through compound screening approaches or using single substances.